The DOI matches its Crossref record; 185 of the 185 references it cites were found in a registry or an index.
The role of ChREBP in carbohydrate sensing and NAFLD development
Open accessAbstract
Excessive sugar consumption and defective glucose sensing by hepatocytes contribute to the development of metabolic diseases including type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD). Hepatic metabolism of carbohydrates into lipids is largely dependent on the carbohydrate-responsive element binding protein (ChREBP), a transcription factor that senses intracellular carbohydrates and activates many different target genes, through the activation of de novo lipogenesis (DNL). This process is crucial for the storage of energy as triglycerides in hepatocytes. Furthermore, ChREBP and its downstream targets represent promising targets for the development of therapies for the treatment of NAFLD and T2DM. Although lipogenic inhibitors (for example, inhibitors of fatty acid synthase, acetyl-CoA carboxylase or ATP citrate lyase) are currently under investigation, targeting lipogenesis remains a topic of discussion for NAFLD treatment. In this Review, we discuss mechanisms that regulate ChREBP activity in a tissue-specific manner and their respective roles in controlling DNL and beyond. We also provide in-depth discussion of the roles of ChREBP in the onset and progression of NAFLD and consider emerging targets for NAFLD therapeutics.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ChREBPβ is transcriptionally induced by ChREBPα and amplifies the glucose response in the liver and adipose tissue [78,86].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [78]
In the citing paper
“Fructose has emerged as a potent activator of carbohydrate response element-binding protein (ChREBP), which is particularly relevant in the context of MASLD, given the global rise in fructose consumption that parallels the increasing prevalence of MASLD [78- 82].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [78]
In the citing paper
“ChREBP, which is a member of the Mondo family of transcription factors, senses carbohydrates and activates genes involved in glycolysis, DNL, and lipid trafficking [2,34,78].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [78]
In the citing paper
“ChREBP, which is activated by carbohydrate uptake [9,34,78,83].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [78]
Citations
Cites
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Metabolic Endotoxemia Initiates Obesity and Insulin Resistance
Cani, P. D., Amar, J., Iglesias, M. A., Poggi, M., Knauf, C., Bastelica, D., Neyrinck, A. M., Fava, F., Tuohy, K. M., Chabo, C., et al. (2007) · Diabetes · doi:10.2337/db06-1491 · Cited by 6,638
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Stanhope, K. L., Schwarz, J. M., Keim, N. L., Griffen, S. C., Bremer, A. A., Graham, J. L., Hatcher, B., Cox, C. L., Dyachenko, A., Zhang, W., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37385 · Cited by 1,765
Cited by
Bo, T., Gao, L., Yao, Z., Shao, S., Wang, X., Proud, C. G., & Zhao, J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.04.006 · Cited by 293
Pharmacologic inhibition of lipogenesis for the treatment of NAFLD
Esler, W. P., & Cohen, D. E. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.10.042 · Cited by 129
Truong, X. T., & Lee, D. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0644 · Cited by 84
“Additionally, metabolic intermediates such as xylulose 5-phosphate, G6P, fructose-2,6-bisphosphate, and acetyl-CoA are additional potential activators of ChREBP translocation and activity [2,34, 78,93].”
InfluentialLiver ALKBH5 regulates glucose and lipid homeostasis independently through GCGR and mTORC1 signaling
Ding, K., Zhang, Z., Han, Z., Shi, L., Li, X., Liu, Y., Li, Z., Zhao, C., Cui, Y., Zhou, L., et al. (2025) · Science · doi:10.1126/science.adp4120 · Cited by 86
Oxidative Stress and Reprogramming of Lipid Metabolism in Cancers
Li, S., Yuan, H., Li, L., Li, Q., Lin, P., & Li, K. (2025) · Antioxidants · doi:10.3390/antiox14020201 · Cited by 84
Metadata
- Authors
- Régnier, M., Carbinatti, T., Parlati, L., Benhamed, F., & Postic, C.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Régnier, Marion
- Postic, Catherine
- Venue
- Nature Reviews Endocrinology
- Published
- 2023-04-13
- Volume
- 19
- Issue
- 6
- Pages
- 336-349
- ISSN
- 1759-5029 (ISSN-L)
- 1759-5037
- OpenAlex
- W4365479160
- Cited by
- 101
- References
- 185
- Citations by year
- 2026: 26 · 2025: 41 · 2024: 30 · 2023: 4
- FWCI
- 3.92
- Type
- journal article
- Language
- en
- Open access
- green
- hal.science
- Licence
- other-oa
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Reviews Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Funders
- Agence Nationale de la Recherche (ANR-17-CE14-0015, ANR-20-CE14-0038)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- ChREBP, carbohydrate sensing, non-alcoholic fatty liver disease, de novo lipogenesis, hepatocytes, type 2 diabetes, fatty acid synthase, acetyl-CoA carboxylase, ATP citrate lyase, triglyceride storage, transcription factor regulation
- MeSH terms
- Carbohydrates, Diabetes Mellitus, Type 2, Humans, Liver, Transcription Factors, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The role of ChREBP in carbohydrate sensing and NAFLD development. https://app.cochat.ai/papers/10.1038/s41574-023-00809-4
- The paper
- Régnier, M., Carbinatti, T., Parlati, L., Benhamed, F., & Postic, C. (2023). The role of ChREBP in carbohydrate sensing and NAFLD development. Nature Reviews Endocrinology. https://doi.org/10.1038/s41574-023-00809-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.